Paper36498473
Pharmacokinetics, Pharmacodynamics, and Dosing Considerations of Novel β-Lactams and β-Lactam/β-Lactamase Inhibitors in Critically Ill Adult Patients: Focus on Obesity, Augmented Renal Clearance, Renal Replacement Therapies, and Extracorporeal Membrane Oxygenation.
Bakdach D and 5 others. J Clin Med, 2022. Cited by 31 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Pharmacokinetics, Pharmacodynamics, and Dosing Considerations of Novel β-Lactams and β-Lactam/β-Lactamase Inhibitors in Critically Ill Adult Patients: Focus on Obesity, Augmented Renal Clearance, Renal Replacement Therapies, and Extracorporeal Membrane Oxygenation. Papers, record 36498473. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36498473
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Pharmacokinetics, Pharmacodynamics, and Dosing Considerations of Novel β-Lactams and β-Lactam/β-Lactamase Inhibitors in Critically Ill Adult Patients: Focus on Obesity, Augmented Renal Clearance, Renal Replacement Therapies, and Extracorporeal Membrane Oxygenation.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References96
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33,292,582 | The higher the better? Defining the optimal beta-lactam target for critically ill patients to reach infection resolution and improve outcome. | J Intensive Care | 2020 | https://conductscience.org/library/papers/33292582 | PubMed |
| 2 | 10,990,106 | Acute renal failure in the ICU: risk factors and outcome evaluated by the SOFA score. | Intensive Care Med | 2000 | https://conductscience.org/library/papers/10990106 | PubMed |
| 3 | 21,333,028 | Antibiotic dosing in the 'at risk' critically ill patient: Linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients. | BMC Anesthesiol | 2011 | https://conductscience.org/library/papers/21333028 | PubMed |
| 4 | 19,397,464 | Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. | Pharmacotherapy | 2009 | https://conductscience.org/library/papers/19397464 | PubMed |
| 5 | 23,642,005 | Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used? | Crit Care | 2013 | https://conductscience.org/library/papers/23642005 | PubMed |
| 6 | 27,451,086 | Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration. | Int J Antimicrob Agents | 2016 | https://conductscience.org/library/papers/27451086 | PubMed |
| 7 | 30,626,244 | Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens. | Expert Opin Drug Metab Toxicol | 2019 | https://conductscience.org/library/papers/30626244 | PubMed |
| 8 | 28,571,493 | Optimizing β-lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective? | Expert Rev Anti Infect Ther | 2017 | https://conductscience.org/library/papers/28571493 | PubMed |
| 9 | 31,358,583 | Population Pharmacokinetics of Unbound Ceftolozane and Tazobactam in Critically Ill Patients without Renal Dysfunction. | Antimicrob Agents Chemother | 2019 | https://conductscience.org/library/papers/31358583 | PubMed |
| 10 | 24,768,475 | Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. | Lancet Infect Dis | 2014 | https://conductscience.org/library/papers/24768475 | PubMed |
| 11 | 28,158,470 | Determining β-lactam exposure threshold to suppress resistance development in Gram-negative bacteria. | J Antimicrob Chemother | 2017 | https://conductscience.org/library/papers/28158470 | PubMed |
| 12 | 16,355,321 | The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. | Clin Infect Dis | 2006 | https://conductscience.org/library/papers/16355321 | PubMed |
| 13 | 34,224,115 | Pharmacokinetics of Commonly Used Antimicrobials in Critically Ill Adults During Extracorporeal Membrane Oxygenation: A Systematic Review. | Drugs | 2021 | https://conductscience.org/library/papers/34224115 | PubMed |
| 14 | 31,325,141 | What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review. | Clin Pharmacokinet | 2019 | https://conductscience.org/library/papers/31325141 | PubMed |
| 15 | 34,034,594 | Oxygenator impact on meropenem/vaborbactam in extracorporeal membrane oxygenation circuits. | Perfusion | 2022 | https://conductscience.org/library/papers/34034594 | PubMed |
| 16 | 27,012,450 | Ceftolozane/Tazobactam Pharmacokinetics in a Critically Ill Adult Receiving Continuous Renal Replacement Therapy. | Pharmacotherapy | 2016 | https://conductscience.org/library/papers/27012450 | PubMed |
| 17 | 15,656,698 | Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration. | Clin Pharmacokinet | 2005 | https://conductscience.org/library/papers/15656698 | PubMed |
| 18 | 34,250,190 | Cefiderocol Pharmacokinetics in a Patient Receiving Continuous Venovenous Hemodiafiltration. | Open Forum Infect Dis | 2021 | https://conductscience.org/library/papers/34250190 | PubMed |
| 19 | 20,862,453 | Determinants of drug absorption in different ECMO circuits. | Intensive Care Med | 2010 | https://conductscience.org/library/papers/20862453 | PubMed |
| 20 | 23,683,557 | Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy. | J Crit Care | 2013 | https://conductscience.org/library/papers/23683557 | PubMed |
Cited by24
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 31 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,802,803 | Model-Informed Ceftazidime-Avibactam Dosing Stratified by Renal Function and Renal Replacement Therapy Status in Critically Ill Patients: A Prospective Population Pharmacokinetic and Monte Carlo Simulation Study. | Drug Des Devel Ther | 2026 | https://conductscience.org/library/papers/42802803 | PubMed |
| 42,781,062 | Prediction of Meropenem Target Attainment in Critically Ill Patients Using Routine Clinical Data from a Single Center: A Machine Learning Approach. | Infect Drug Resist | 2026 | https://conductscience.org/library/papers/42781062 | PubMed |
| 42,353,742 | Real-World Evidence: Cefiderocol Therapeutic Drug Monitoring in Critically Ill, Obese Patients with Klebsiella pneumoniae Infections. | Antibiotics (Basel) | 2026 | https://conductscience.org/library/papers/42353742 | PubMed |
| 41,892,463 | Prescribing Patterns and Clinical Outcomes of Ceftolozane/Tazobactam by Renal Function and Body Mass Index: A SPECTRA Real-World Multi-Country Analysis. | Antibiotics (Basel) | 2026 | https://conductscience.org/library/papers/41892463 | PubMed |
| 41,859,700 | Antimicrobial Pharmacokinetic and Pharmacodynamic Considerations in Special Populations: A Call to Action. | Open Forum Infect Dis | 2026 | https://conductscience.org/library/papers/41859700 | PubMed |
| 41,283,612 | Optimizing Drug Therapy in ECMO-Supported Critically Ill Adults: A Narrative Review and Clinical Guide. | Pharmacy (Basel) | 2025 | https://conductscience.org/library/papers/41283612 | PubMed |
| 41,239,168 | PK/PD study of ceftazidime/avibactam in patients with severe intra-abdominal infections treated by continuous veno-venous hemofiltration. | Eur J Clin Microbiol Infect Dis | 2026 | https://conductscience.org/library/papers/41239168 | PubMed |
| 40,852,616 | Continuous infusion versus intermittent dosing of ceftazidime/avibactam in critically ill patients with Klebsiella pneumoniae OXA-48 or Pseudomonas aeruginosa infections: a single-center randomized open-label trial (ZAVICONT). Rationale and design. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40852616 | PubMed |
| 39,596,718 | Impact of Extracorporeal Membrane Oxygenation (ECMO) on Serum Concentrations of Cefepime. | Antibiotics (Basel) | 2024 | https://conductscience.org/library/papers/39596718 | PubMed |
| 39,530,161 | Dynamic distribution of systemically administered antibiotics in orthopeadically relevant target tissues and settings. | APMIS | 2024 | https://conductscience.org/library/papers/39530161 | PubMed |
| 39,425,201 | Cefiderocol pharmacokinetics in critically ill patients undergoing ECMO support. | Crit Care | 2024 | https://conductscience.org/library/papers/39425201 | PubMed |
| 39,384,682 | In vivo development of resistance to novel β-lactam/β-lactamase inhibitor combinations in KPC-producing Klebsiella pneumoniae infections: a case series. | Eur J Clin Microbiol Infect Dis | 2024 | https://conductscience.org/library/papers/39384682 | PubMed |
| 39,061,311 | Novel Antibiotics for Gram-Negative Nosocomial Pneumonia. | Antibiotics (Basel) | 2024 | https://conductscience.org/library/papers/39061311 | PubMed |
| 39,035,618 | Understanding antimicrobial pharmacokinetics in critically ill patients to optimize antimicrobial therapy: A narrative review. | J Intensive Med | 2024 | https://conductscience.org/library/papers/39035618 | PubMed |
| 39,005,857 | Adequacy of the Dosing and Infusion Time of Ceftazidime/Avibactam for the Treatment of Gram-Negative Bacterial Infections: A PK/PD Simulation Study. | Infect Drug Resist | 2024 | https://conductscience.org/library/papers/39005857 | PubMed |
| 38,786,181 | Role of Cefiderocol in Multidrug-Resistant Gram-Negative Central Nervous System Infections: Real Life Experience and State-of-the-Art. | Antibiotics (Basel) | 2024 | https://conductscience.org/library/papers/38786181 | PubMed |
| 38,526,051 | Updated antimicrobial dosing recommendations for obese patients. | Antimicrob Agents Chemother | 2024 | https://conductscience.org/library/papers/38526051 | PubMed |
| 38,433,781 | Model-Informed Precision Dosing of Imipenem in an Obese Adolescent Patient with Augmented Renal Clearance and History of Schizophrenia. | Infect Drug Resist | 2024 | https://conductscience.org/library/papers/38433781 | PubMed |
| 38,099,629 | Meropenem extraction by ex vivo extracorporeal life support circuits. | J Extra Corpor Technol | 2023 | https://conductscience.org/library/papers/38099629 | PubMed |
| 37,720,698 | Weighing the Odds: Novel β-Lactam/β-Lactamase Inhibitor Use in Hospital-Acquired and Ventilator-Associated Pseudomonas aeruginosa Pneumonia for Patients Who Are Morbidly Obese. | Open Forum Infect Dis | 2023 | https://conductscience.org/library/papers/37720698 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CRCL | 261,727 | PubTator's text mining | https://conductscience.org/library/genes/261727 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36498473
GET https://conductscience.org/api/papers/v1/36498473/references?page=2